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Abstract
Purpose—The National Breast and Cervical Cancer Early Detection Program (NBCCEDP) 
enrolls asymptomatic women for cancer screening and symptomatic women for diagnostic 
services. Tiris study describes the results of mammograms provided by the NBCCEDP, by 
examination indication (screening or diagnostic), and by age group.
Methods—For the first NBCCEDP-funded mammogram received during 2009–2012, we 
calculated age-specific percentages of abnormal findings, rates of follow-up testing, and invasive 
and in situ breast cancer diagnoses per 1,000 mammograms. Logistic regression was used to 
estimate the odds for each of these outcomes by examination indication.
Results—The NBCCEDP provided 941,649 screening, 175,310 diagnostic, and 30,434 unknown 
indication mammograms to 1,147,393 women. The percentage with abnormal mammograms was 
higher for diagnostic mammograms (40.1 %) than for screening mammograms (15.5 %). 
Compared with women aged 40–49 years, fewer women aged 50–64 years had abnormal results 
for screening (13.7 vs. 19.7 %) and diagnostic mammograms (37.7 vs. 42.7 %). Follow-up rates 
per 1,000 mammograms were lower among women aged 50–64 compared to those aged 40–49 
(screening: 143.9 vs. 207.5; diagnostic: 645.3 vs. 760.9); biopsy rates exhibited a similar pattern 
(screening: 24.1 vs. 32.9; diagnostic: 167.7 vs. 169.7). For screening mammograms, older women 
had more cancers detected than younger women (invasive: 3.6 vs. 2.2; in situ: 2.3 vs. 2.0). 
Similarly, for diagnostic mammograms, cancer detection was higher for older women (invasive: 
67.8 vs. 36.6; in situ: 17.4 vs. 11.1).
Conclusions—Abnormal mammograms and diagnostic follow-up procedures were less frequent 
in women aged 50–64 years compared to women aged 40–49 years, while breast cancer detection 
was higher, regardless of indication for the mammogram. Some of these differences between age 
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groups were greater for screening mammograms than for diagnostic mammograms. Cancer 
detection rates were higher for diagnostic mammograms compared with screen ing mammograms. 
These findings support the NBCCEDP's priority of serving women aged 50–64 years and 
providing both screening and diagnostic mammograms.
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Introduction
To improve access to cancer screening among low-income, uninsured women, the US 
Congress passed the Breast and Cervical Cancer Mortality Prevention Act of 1990 (Public 
Law 101-354), which created the National Breast and Cer vical CancerEarly Detection 
Program (NBCCEDP) [1].This nationwide, comprehensive public health program is 
administered through the Centers for Disease Control and Prevention (CDC) and provides 
uninsured, underinsured, and underserved women with access to screening services for the 
early detection of breast and cervical cancer [1]. Eligibility is limited to women with 
incomes less than or equal to 250 % of the federal poverty level and who are uninsured or 
underinsured. Underinsured includes women who have insurance that does not cover breast 
cancer screening and women who cannot afford their insurance deductibles or copays. 
Because resources are limited, programs have been directed to focus on screening women 
aged 50–64 years. The NBCCEDP requires that at least 75 % of all program-paid 
mammograms be provided to this priority population [1]. States often use other funds to 
provide services to women aged 40–49 years.
The NBCCEDP priority age population is consistent with recommendations from the US 
Preventive Services Task Force (USPSTF) [2]. For many years, the USPSTF recommended 
screening mammography, with or without a clinical breast examination for women aged 40 
years and older. However, the 2009 update to the USPSTF changed the recommendation 
from annual to biennial screening mammography for all women aged 50–74 years. Routine 
screening before the age of 50 years was not recommended, yet should be supported if a 
woman chooses to be screened [2]. These changes in the recommendation were supported 
by evidence from randomized controlled trials, which have shown that the absolute benefit 
of screening is greater in women aged 50–74 years than in women aged 40–49 [2].
Previous studies of the NBCCEDP have demonstrated that women aged 40–49 years had the 
highest rates of abnormal mammograms and of diagnostic follow-up but lower rates of 
cancer detection [3, 4]. However, these studies did not account for whether indication for 
receiving the mammogram was screening or diagnostic. It is possible that younger women 
(aged 40–49 years) are more likely than older women (aged 50–64 years) to receive a 
mammogram for diagnostic purposes. It is unclear whether differences exist in screening 
outcomes between these age groups when accounting for whether the indication for the 
mammogram was screening versus diagnostic. Therefore, we examined whether 
mammography findings, diagnostic follow-up, and cancer detection in the NBCCEDP’s 
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priority population of older women (aged 50–64 years) differed from younger women (aged 
40–49 years) by mammography indication during 2009 through 2012.
Materials and methods
Data sources
The NBCCEDP has been implemented in all 50 states, the District of Columbia, some US 
territories, and American Indian/Alaska Native tribes and tribal organizations [1]. 
NBCCEDP data were obtained for breast cancer screening, referral, and follow-up provided 
by these programs. Grantees regularly report a set of standardized surveillance and 
evaluation data, known as minimum data elements (MDEs), to CDC. These datasets include 
variables that are minimally necessary to monitor client demographics, track clinical 
outcomes, establish policies and practices, assess screening outcomes, and respond to the 
informational needs of CDC stakeholders and partners [1].
The NBCCEDP collects variables related to demographics, clinical breast examination 
(CBE) results, indication for initial mammogram, mammogram results, diagnostic 
procedures, and final diagnosis. Self-reported demographics including race, ethnicity, and 
age are also available. Women who identified as Hispanic were classified as such, regardless 
of race. Race was categorized for non-Hispanic groups as follows: white, black, American 
Indian/Alaska Native, Asian/Pacific Islander, and multiracial or unknown. Age was 
categorized to allow comparison between the priority population (aged 50–64 years and 
non-Medicare enrolled) and younger women (aged 40–49 years). Residence was based on 
each woman’s county of residence linked with the corresponding US Department of 
Agriculture urban–rural continuum code and classified as metropolitan, urban, rural area, or 
unknown [5]. Also, region of residence was categorized by Census region [6]. Tribes and 
territories were classified in the same region as the states where they are located. Providers 
reported dates and results of CBEs, mammograms, diagnostic procedures, and outcomes. 
Results for CBEs, classified as normal, abnormal, or unknown, are not reported in this 
paper.
For MDE reporting and this analysis, the initial mammogram begins a breast screening 
record and is used to report screening results, and the indication for the initial mammogram 
is used to distinguish routine screening from problem-focused screening. The results of 
additional diagnostic follow-up procedures are used to report the diagnostic outcomes of the 
screening process. Indication for the initial mammogram was categorized as screening or 
diagnostic. Screening indication was assigned to initial mammograms performed as part of a 
routine screening schedule and in the absence of symptoms or a recent positive CBE; 
diagnostic indication included initial mammograms performed to evaluate symptoms, an 
abnormal CBE, or recent abnormal mammogram result. Mammograms for women referred 
into the NBCCEDP for diagnostic evaluation because of previous initial abnormal breast 
cancer screening results were also classified as diagnostic indication, and the referral date 
was used when the mammography examination date was missing. Mammograms of 
unknown indication only represented 2.7 % and were excluded from the analyses.
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Mammogram results were reported using the American College of Radiology’s Breast 
Imaging Reporting and Data System (BI-RADS) categories: assessment incomplete 
(category 0), normal (category 1), benign (category 2), probably benign (category 3), 
suspicious abnormality (category 4), and highly suggestive of malignancy (category 5) [7]. 
Abnormal mammograms were defined by the following BI-RAD categories: suspicious 
abnormality (category 4), highly suggestive of malignancy (category 5), or assessment 
incomplete (category 0). The percentage of abnormal mammograms was calculated. 
Diagnostic follow-up consists of any surgical or imaging procedures other than the 
screening mammogram or CBE, including additional mammographic views, ultrasound, a 
repeat CBE or surgical consultation, a fine-needle or cyst aspiration, and biopsy [1]. The 
NBCCEDP requires all women with abnormal results for CBEs or abnormal mammograms 
to undergo diagnostic follow-up [1]. The rate of diagnostic follow-up was calculated per 
1,000 mammograms for the study period and defined by the number of mammogram records 
where at least one subsequent diagnostic procedure was performed regardless of 
mammogram result. The biopsy rate was based on the number of incisional, excisional, or 
core biopsies per 1,000 mammograms during this time period. The cancer detection rate was 
estimated per 1,000 mammograms and defined by the number of invasive cancers and in situ 
cancers diagnosed.
Study population
The study population consisted of women aged 40–64 years who had an initial NBCCEDP 
mammogram during 1 January 2009 through 31 December 2012. Only the women’s first 
NBCCEDP mammogram in the selected time period was included in the analysis regardless 
of whether they reported a previous mammogram elsewhere. Many women only receive one 
mammogram through the NBCCEDP. Results from subsequent mammograms were not 
included. After all exclusions, our final study population consisted of 1,147,393 unique 
women with a mammogram during this time period.
Data analysis
Demographic and clinical characteristics of women receiving an initial mammogram from 
2009 to 2012 were summarized using percentages by age group. Further, all percentages and 
rates were calculated by age group (40–49, 50–59, 60–64, 50–64, or total). Few differences 
were noted between women aged 50–59 years and 60–64 years, so these categories were 
collapsed. Using logistic regression, adjusted odds ratios (aORs), and corresponding 95 % 
confidence intervals (CIs) were estimated for women with a screening indication 
mammogram and women with a diagnostic indication mammogram for the odds of an 
abnormal mammogram, diagnostic follow-up, final diagnosis of in situ breast cancer, and 
final diagnosis of invasive breast cancer. All models were adjusted for age, race, rural or 
urban residence, and region. All analyses were performed using SAS software version 9.2 
(SAS Institute, Cary, North Carolina).
White et al. Page 4















From 2009 to 2012, 1,147,393 women received a mammogram through the NBCCEDP 
(Table 1). Of these women, most (67.1 %) were aged 50–64 years. Almost half (46.7 %) of 
the women were white, non-Hispanic followed by Hispanic (24.4 %) and black non-
Hispanic (18.1 %) women. Many women resided in metropolitan areas (74.0 %) and in the 
South (34.1 %). Most (82.1 %) women received a mammogram for screening, while 15.3 % 
received a diagnostic mammogram. Mammography indication was unknown for 2.7 % of 
women, and therefore, these mammograms were excluded from subsequent analyses. 
Compared to 40- to 49-year-old women, a higher percentage of women aged 50–64 years 
were black, non-Hispanic (19.2 % vs. 15.8 %) or Asian/Pacific Islander (6.5 % vs. 3.9 %), 
resided in the South (36.5 % vs. 29.1 %) or West (25.4 % vs. 19.3 %), and received a 
mammogram for screening purposes (85.4 % vs. 75.4 %). The percentage of women who 
received a mammogram and were diagnosed with invasive cancer was similar for women 
aged 40–49 years (1.0 %; n = 3,752) and 50–59 years (1.1 %; n = 6,083) and slightly higher 
(1.4 %; n = 2,752) for women aged 60–64 years.
Table 2 shows findings for mammograms by age group and indication for mammogram. 
Overall, 15.5 % of all screening mammograms were abnormal compared with 40.1 % of all 
diagnostic mammograms. For screening mammograms, fewer 50- to 64-year-old women 
had abnormal results (13.7 %) than 40- to 49-year-olds (19.7 %). Similarly, for diagnostic 
mammograms, 37.7 % of 50- to 64-year-old women had abnormal results compared to 42.7 
% of 40- to 49-year-old women.
There were also differences in diagnostic follow-up and cancer detection by mammogram 
indication (Table 3). Overall, compared with screening mammograms, diagnostic 
mammograms were followed by significantly more diagnostic procedures (699.7 vs. 163.1) 
and biopsies (168.7 vs. 26.8) per 1,000 mammograms. Cancer detection rates for diagnostic 
mammograms were higher than screening mammograms for invasive (53.1 vs. 3.2) and in 
situ (14.5 vs. 2.2) cancers. For screening mammograms, 50- to 64-year-olds had fewer 
diagnostic procedures (143.9 vs. 207.5) and biopsies (24.1 vs. 32.9) per 1,000 mammograms 
compared with 40- to 49-year-olds. In spite of this, 50- to 64-year-olds had more invasive 
cancers (3.6 vs. 2.2) or in situ cancers (2.3 vs. 2.0) detected per 1,000 mammograms than 
40- to 49-year-olds. Similarly, for diagnostic mammograms, 50- to 64-year-old women had 
fewer diagnostic procedures (645.3 vs. 760.9) and biopsies (167.7 vs. 169.7), yet greater 
cancer detection (invasive: 67.8 vs. 36.6; in situ: 17.4 vs. 11.1) than 40- to 49-year-old 
women.
Table 4 shows the adjusted odds for having an abnormal result by mammogram indication. 
Among women with a screening mammogram, the odds of having an abnormal result were 
lower for 50- to 64-year-olds (aOR = 0.65; 95 % CI 0.64–0.66) compared with 40- to 49-
year-olds after adjusting for race, residence, and region. Among those with a diagnostic 
mammogram, the pattern was similar but the difference between age groups was less (50- to 
64-year-olds: aOR = 0.82; 95 % CI 0.80–0.83). Finally, although there were statistically 
significant differences for screening mammograms by race/ethnicity, for abnormal 
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diagnostic mammograms, only American Indian/Alaska Natives (aOR 1.13; 95 % CI 1.05–
1.22) and Hispanics (aOR 0.86; 95 % CI 0.84–0.88) differed from whites (Table 4).
In Table 5, the odds of having any diagnostic follow-up are presented by mammogram 
indication. The odds of having diagnostic follow-up were lower for 50- to 64-year-old 
women (aOR = 0.64; 95 % CI 0.63–0.65) than for 40- to 49-year-old women among those 
with a screening indication; among those with a diagnostic indication, the pattern was 
similar but the difference between the age groups was greater (aOR = 0.57; 95 % CI 0.55–
0.58).
Table 6 presents the odds of having a final diagnosis of carcinoma in situ by mammogram 
indication. In situ cancer detection was greater for 50- to 64-year-old women than for 40- to 
49-year-old women for screening indication (aOR = 1.15; 95 % CI 1.05–1.27). For 
diagnostic indication, the difference was even greater for 50- to 64-year-old women 
compared with younger women (aOR = 1.51; 95 % CI 1.39 1.64).
Table 7 displays the odds of having a final diagnosis of invasive cancer by mammogram 
indication. Women aged 50–64 years had higher invasive cancer detection rates than 40- to 
49-year-olds, regardless of indication (screening indication: aOR = 1.60; 95 % CI 1.47–1.75; 
diagnostic indication: aOR = 1.85; 95 % CI 1.77–1.94); however, the difference was greater 
for those with a diagnostic indication. Among women with diagnostic mammograms, only 
Hispanics (aOR 0.47, 95 % CI 0.44–0.50) and American Indians/Alaska natives (aOR 0.83, 
95 % CI 0.69–0.99) differed from whites, with lower odds of having a final diagnosis of 
invasive cancer (Table 7).
Discussion
In this study, significant differences in breast cancer screening clinical outcomes were noted 
between the NBCCEDP’s priority population (aged 50–64 years) and younger women (aged 
40–49 years) who received services through the NBCCEDP, with some variation by 
mammography indication. First, 50- to 64-year-old women had fewer abnormal 
mammograms regardless of screening or diagnostic indication, although the difference 
between the age groups was greater for screening indication. Furthermore, the priority 
population had less diagnostic follow-up than younger women; these differences were 
greater among women with diagnostic mammograms. Cancer detection was higher for the 
priority population than for younger women. Overall, cancer detection was higher for 
diagnostic mammograms than for screening mammograms.
Previous studies have examined breast cancer screening clinical outcomes in the NBCCEDP 
[3, 4]. The higher rates of abnormal mammograms and diagnostic follow-up for women 
aged 40–49 years compared with women aged 50–64 years, regardless of the type of service 
received, are partially explained by greater breast density in younger women [8]. Higher 
breast density decreases the sensitivity of mammography for detecting breast cancer and 
increases false-positive results, leading to higher recall rates [8]. The value of screening 
mammography for younger women remains an active area of discussion and debate.
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This study is the first to examine screening outcomes by mammography indication in the 
NBCCEDP. Although the NBCCEDP does not make a distinction between the need for 
screening or diagnostic services when enrolling women, there is a focus on women at high 
risk of cancer. NBCCEDP-eligible women with symptoms or abnormal clinical breast 
examinations are at increased risk of having breast cancer and therefore have greater need 
for available services. Furthermore, many women served through the NBCCEDP do not 
receive routine preventive health care; the NBCCEDP is their only source for breast cancer 
detection and treatment services [1]. These data showed that overall breast cancer detection 
was much higher for diagnostic mammograms than for screening mammograms. This 
finding further supports the NBCCEDP’s focus on providing both screening and diagnostic 
mammograms to medically underserved women at high risk of breast cancer. The 
NBCCEDP’s focus on high-risk women is evident when comparing findings with the Breast 
Cancer Surveillance Consortium (BCSC), a collaborative network of seven mammography 
registries across the nation with linkages to tumor and/or pathology registries that include 
women of all incomes and insurance status. These data allow examination of the delivery 
and quality of breast cancer screening and outcomes. In the NBCCEDP, the overall cancer 
detection rates for screening mammograms are higher for both screening (5.4 vs. 4.1 per 
1,000) and diagnostic mammograms (67.7 vs. 29.3 per 1,000). Although the overall rates 
include different age groups (NBCCEDP aged 40–64 years; BCSC aged 18–80+ years), 
cancer detection in the NBCCEDP is higher for women aged 40–49 years and 50–64 years.
Similar patterns in outcomes for screening and diagnostic mammograms were observed 
between the priority population and younger women. However, the difference in follow-up 
and cancer detection between women aged 50–64 years and women aged 40–49 years was 
greater for diagnostic mammograms (115.6 per 1,000; 37.5 per 1,000, respectively) than for 
screening mammograms (63.6 per 1,000; 1.7 per 1,000). This finding was expected because 
some programs only see young women if they are symptomatic. Racial differences in 
abnormal mammograms and cancer detection varied by indication for mammography. 
Among those with diagnostic mammography indication, there were no differences in 
abnormal mammograms and invasive cancer detection observed for black, Asian/Pacific 
Islander or multiracial/unknown women compared with white women. The odds of having 
abnormal mammograms or invasive cancers detected were lower for these groups compared 
with whites for screening indication. It is unclear why racial differences exist for screening 
indication but not for diagnostic indication.
The NBCCEDP breast cancer screening results are subject to limitations. First, this study 
focused on breast cancer screening and follow-up in organized state-based screening 
programs and may have limited generalizability to uninsured and low-income women in 
other settings. Second, we classified women who were referred into the NBCCEDP as 
receiving diagnostic services. It is unclear the extent to which these women might have been 
referred for “true” screening. Finally, despite standardized data collection documents, there 
may be variation across programs in the methods used for data collection, especially in 
regard to self-reported variables.
In conclusion, the findings show that compared with women aged 40–49 years, the 
NBCCEDP’s priority population (aged 50–64 years) had fewer abnormal mammograms, 
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less diagnostic follow-up, and higher breast cancer detection, regardless of indication for the 
mammogram. Furthermore, cancer detection rates for all ages were much higher for 
diagnostic mammograms than for screening mammograms. These outcomes not only 
support the NBCCEDP’s policy of focusing priority on screening women aged 50–64 years 
but also highlight the need to continue to offer services to women aged 40–49 years who 
may be at high risk of developing breast cancer. By providing both screening and diagnostic 
mammograms, the NBCCEDP offers much-needed services to this high-risk population. 
However, the NBCCEDP only reaches about 11 % of all eligible women [9]. More targeted 
public health efforts are needed to improve access to screening, timely follow-up, and 
treatment for breast cancer for all women in the USA.
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Table 1
Characteristics of women receiving a mammogram
a
 through the National Breast and Cervical Cancer Early 
Detection Program by age group (n = 1,147,393), 2009–2012
Total (40–64 years) 40–49 years 50–64 years
n % n % n %
Total 1,147,393 100.0 377,001 100.0 770,392 100.0
Race/ethnicity
 White, non-Hispanic 536,206 46.7 175,547 46.6 360,659 46.8
 Black, non-Hispanic 207,135 18.1 59,518 15.8 147,617 19.2
 Asian/Pacific Islander 64,688 5.6 14,520 3.9 50,168 6.5
 American Indian/Alaska Native 35,189 3.1 12,147 3.2 23,042 3.0
 Hispanic 279,934 24.4 107,464 28.5 172,470 22.4
 Multiracial/unknown 24,241 2.1 7,805 2.1 16,436 2.1
Residence
 Urban/rural continuum
 Metro 849,168 74.0 273,818 72.6 575,350 74.7
 Urban 251,507 21.9 87,069 23.1 164,438 21.3
 Rural 43,779 3.8 15,188 4.0 28,591 3.7
 Unknown 2,939 0.3 926 0.2 2,013 0.3
Region where services were provided
 Northeast 183,645 16.0 70,891 18.8 112,754 14.6
 Midwest 304,540 26.5 123,342 32.7 181,198 23.5
 South 390,946 34.1 109,831 29.1 281,115 36.5
 West 268,262 23.4 72,937 19.3 195,325 25.4
Type of service women received/indication for initial mammogram
 Unknown 30,434 2.7 10,494 2.8 19,940 2.6
 Screening 941,649 82.1 284,110 75.4 657,539 85.4
 Diagnostic 175,310 15.3 82,397 21.9 92,913 12.1
Cancer diagnoses
Invasive cancer
Yes 12,587 1.1 3,752 1.0 8,835 1.1
No 1,134,806 98.9 373,249 99.0 761,557 98.9
Carcinoma in situ
Yes 4,702 0.4 1,510 0.4 3,192 0.4
No 1,142,691 99.6 375,491 99.6 767,200 99.6
a
Based on women’s initial mammogram during 2009–2012
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Table 2
Breast cancer screening test results by age group and mammogram indication, National Breast and Cervical 
Cancer Early Detection Program, 2009–2012
Total (40–64 years) 40–49 years 50–64 years
n % n % n %
Indication of screening
Total screening mammograms 941,649 100.0 284,110 100.0 657,539 100.0
Normal
 Total normal 795,825 84.5 228,243 80.3 567,582 86.3
 Negative 452,497 48.1 140,226 49.4 312,271 47.5
 Benign 329,550 35.0 83,112 29.3 246,438 37.5
 Probably benign 13,506 1.4 4,791 1.7 8,715 1.3
 Unsatisfactory 272 <0.1 114 <0.1 158 <0.1
Abnormal
 Total abnormal 145,824 15.5 55,867 19.7 89,957 13.7
 Suspicious abnormality 3,856 0.4 1,450 0.5 2,406 0.4
 Highly suggestive of malignancy 732 0.1 187 0.1 545 0.1
 Assessment incomplete 136,357 14.5 52,812 18.6 83,545 12.7
 Non-program 7 <0.1 1 <0.1 6 <0.1
 Film comparison required 4,872 0.5 1,417 0.5 3,455 0.5
Indication of diagnostic
Total diagnostic mammograms 175,310 100.0 82,397 100.0 92,913 100.0
Normal
 Total normal 105,093 59.9 47,203 57.3 57,890 62.3
 Negative 38,320 21.9 17,572 21.3 20,748 22.3
 Benign 53,423 30.5 23,073 28.0 30,350 32.7
 Probably benign 13,303 7.6 6,533 7.9 6,770 7.3
 Unsatisfactory 47 <0.1 25 <0.1 22 <0.1
Abnormal
 Total abnormal 70,217 40.1 35,194 42.7 35,023 37.7
 Suspicious abnormality 12,071 6.9 6,042 7.3 6,029 6.5
 Highly suggestive of malignancy 4,860 2.8 1,494 1.8 3,366 3.6
 Assessment incomplete 51,145 29.2 26,676 32.4 24,469 26.3
 Non-program 916 0.5 478 0.6 438 0.5
 Film comparison required 1,225 0.7 504 0.6 721 0.8
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Table 3
Diagnostic follow-up of abnormal mammograms
a
 and cancer detection rates
b
 among women by age group and 
mammogram indication, National Breast and Cervical Cancer Early Detection Program, 2009–2012
Total (40–64 years) 40–49 years 50–64 years
n Per 1,000 n Per 1,000 n Per 1,000
Indication of screening
Total 941,649 1,000.0 284,110 1,000.0 657,539 1,000.0
Any diagnostic procedure
 Yes 153,591 163.1 58,960 207.5 94,631 143.9
 No 788,058 836.8 225,150 792.4 562,908 856.0
Breast biopsy
 Yes 25,267 26.8 9,355 32.9 15,912 24.1
 No 916,382 973.1 274,755 967.0 641,627 975.8
Invasive cancer or CIS
 Yes 5,120 5.4 1,221 4.2 3,899 5.9
 No 936,529 994.5 282,889 995.7 653,640 994.0
Invasive cancer
 Yes 3,036 3.2 651 2.2 2,385 3.6
 No 938,613 996.7 283,459 997.7 655,154 996.3
Carcinoma in situ
 Yes 2,084 2.2 570 2.0 1,514 2.3
 No 939,565 997.7 283,540 997.9 656,025 997.6
Indication of diagnostic
Total 175,310 1,000.0 82,397 1,000.0 92,913 1,000.0
Any diagnostic procedure
 Yes 122,668 699.7 62,704 760.9 59,964 645.3
 No 52,642 300.2 19,693 239.0 32,949 354.6
Breast biopsy
 Yes 29,576 168.7 13,986 169.7 15,590 167.7
 No 145,734 831.2 68,411 830.2 77,323 832.2
Invasive or CISc
 Yes 11,871 67.7 3,943 47.8 7,928 85.3
 No 163,439 932.2 78,454 952.1 84,985 914.6
Invasive cancer
 Yes 9,326 53.1 3,023 36.6 6,303 67.8
 No 165,984 946.8 79,374 963.3 86,610 932.1
Carcinoma in situ
 Yes 2,545 14.5 920 11.1 1,625 17.4
 No 172,765 985.4 81,477 988.8 91,288 982.5
a
Abnormal mammograms include suspicious abnormality, highly suggestive of malignancy, or assessment incomplete
b
Rates are calculated per 1,000 mammograms
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c
Carcinoma in situ
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Table 4
Logistic regression (aOR and 95 % CI) for having an abnormal result by mammogram indication















 40–49 1.0 REF 1.0 REF
 50–64 0.65 0.64 0.66 <0.0001 0.82 0.80 0.83 <0.0001
Race/ethnicity
 White, non-Hispanic 1.0 REF 1.0 REF
 Black, non-Hispanic 0.97 0.96 0.99 0.0005 1.01 0.98 1.04 0.5054
 Asian/Pacific Islander 0.83 0.81 0.85 <0.0001 1.02 0.97 1.08 0.4643
 American Indian/Alaska
  Native
0.80 0.77 0.83 <0.0001 1.13 1.05 1.22 0.0019
 Hispanic 0.90 0.89 0.91 <0.0001 0.86 0.84 0.88 <0.0001
 Multiracial/unknown 0.96 0.92 0.9997 0.0483 0.94 0.88 1.01 0.0827
Metro 1.0 REF 1.0 REF
 Urban 0.85 0.84 0.86 <0.0001 0.87 0.85 0.89 <0.0001
 Rural 0.79 0.76 0.81 <0.0001 0.86 0.81 0.91 <0.0001
 Unknown 1.54 1.39 1.70 <0.0001 1.07 0.84 1.35 0.6052
Region
 West 1.0 REF 1.0 REF
 Northeast 1.36 1.33 1.38 <0.0001 1.19 1.15 1.23 <0.0001
 Midwest 1.04 1.02 1.06 <0.0001 1.06 1.03 1.09 <0.0001
 South 1.15 1.13 1.17 <0.0001 0.85 0.83 0.87 <0.0001
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Table 5
Logistic regression results (aOR and 95 % CI) for having any diagnostic follow-up by mammogram indication













 40–49 1.0 REF 1.0 REF
 50–64 0.64 0.63 0.65 <0.0001 0.57 0.55 0.58 <0.0001
Race/ethnicity
 White, non-Hispanic 1.0 REF 1.0 REF
 Black, non-Hispanic 0.93 0.91 0.94 <0.0001 0.86 0.83 0.88 <0.0001
 Asian/Pacific Islander 0.86 0.84 0.89 <0.0001 0.88 0.83 0.93 <0.0001
 American Indian/Alaska Native 0.77 0.75 0.80 <0.0001 1.08 0.99 1.18 0.0725
 Hispanic 0.88 0.87 0.90 <0.0001 0.86 0.84 0.89 <0.0001
 Multiracial/unknown 0.94 0.90 0.98 0.0020 0.91 0.85 0.98 0.0122
Residence
 Metro 1.0 REF 1.0 REF
 Urban 0.86 0.84 0.87 <0.0001 0.77 0.75 0.79 <0.0001
 Rural 0.78 0.76 0.81 <0.0001 0.74 0.70 0.78 <0.0001
 Unknown 1.42 1.29 1.57 <0.0001 1.02 0.79 1.33 0.8878
Region
 West 1.0 REF 1.0 REF
 Northeast 1.29 1.27 1.32 <0.0001 1.26 1.21 1.31 <0.0001
 Midwest 1.03 1.01 1.05 0.0012 1.20 1.17 1.24 <0.0001
 South 1.14 1.12 1.16 <0.0001 1.25 1.21 1.28 <0.0001
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Table 6
Logistic regression results (aOR and 95 % CI) for having a final diagnosis of carcinoma in situ by 
mammogram indication













 40–49 1.0 REF 1.0 REF
 50–64 1.15 1.05 1.27 0.0039 1.51 1.39 1.64 <0.0001
Race/ethnicity
 White, non-Hispanic 1.0 REF 1.0 REF
 Black, non-Hispanic 0.96 0.85 1.07 0.4466 0.97 0.87 1.08 0.5863
 Asian/Pacific Islander 0.76 0.61 0.92 0.0057 1.35 1.11 1.64 0.0033
 American Indian/Alaska Native 1.05 0.81 1.33 0.7195 0.84 0.58 1.17 0.3227
 Hispanic 0.61 0.53 0.69 <0.0001 0.58 0.51 0.65 <0.0001
 Multiracial/unknown 0.66 0.45 0.92 0.0134 0.77 0.56 1.03 0.0800
Residence
 Metro 1.0 REF 1.0 REF
 Urban 0.83 0.74 0.93 0.0009 0.98 0.89 1.09 0.7577
 Rural 0.91 0.72 1.13 0.3931 0.98 0.78 1.20 0.8167
 Unknown 1.08 0.38 2.38 0.8616 0.88 0.27 2.10 0.8003
Region
 West 1.0 REF 1.0 REF
 Northeast 1.29 1.12 1.50 0.0006 1.23 1.06 1.43 0.0070
 Midwest 1.28 1.12 1.46 0.0004 1.15 1.01 1.30 0.0299
 South 1.12 0.98 1.29 0.0885 1.38 1.23 1.55 <0.0001
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Table 7
Logistic regression results (aOR and 95 % CI) for having a final diagnosis of invasive cancer by mammogram 
indication













 40–49 1.0 REF 1.0 REF
 50–64 1.60 1.47 1.75 <0.0001 1.85 1.77 1.94 <0.0001
Race/ethnicity
 White, non-Hispanic 1.0 REF 1.0 REF
 Black, non-Hispanic 0.74 0.67 0.81 <0.0001 1.01 0.95 1.07 0.8370
 Asian/Pacific Islander 0.57 0.48 0.68 <0.0001 0.95 0.85 1.07 0.3973
 American Indian/Alaska Native 0.62 0.49 0.79 <0.0001 0.83 0.69 0.99 0.0374
 Hispanic 0.43 0.39 0.48 <0.0001 0.47 0.44 0.50 <0.0001
 Multiracial/unknown 0.67 0.50 0.87 0.0024 1.0 0.86 1.15 0.9720
Residence
 Metro 1.0 REF 1.0 REF
 Urban 0.87 0.80 0.96 0.0029 0.90 0.85 0.95 <0.0001
 Rural 0.73 0.59 0.88 0.0008 0.97 0.86 1.08 0.5481
 Unknown 2.31 1.31 3.78 0.0054 0.91 0.50 1.51 0.7237
Region
 West 1.0 REF 1.0 REF
 Northeast 0.93 0.82 1.06 0.2602 0.95 0.88 1.03 0.2431
 Midwest 1.38 1.24 1.54 <0.0001 1.11 1.05 1.18 0.0007
 South 0.90 0.81 1.01 0.0667 1.00 0.95 1.06 0.9354
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